Form 4: ClearPoint Neuro Director Acquires Restricted Stock Units

Timothy T. Richards, a Director at ClearPoint Neuro, Inc., acquired 12,820 restricted stock units on May 21, 2026, as detailed in a Form 4 filing.

Summary

• Timothy T. Richards, a Director of ClearPoint Neuro, Inc. (CLPT), was granted 12,820 restricted stock units (RSUs) on May 21, 2026.
• Each RSU represents a contingent right to receive one share of CLPT common stock.
• These RSUs are set to vest on the earlier of the first anniversary of the grant date or the day before the Company's 2027 annual meeting of stockholders.

Sentiment

Score: 5

Explanation: StockSavvy.ai views this as a neutral filing, as it represents a standard director equity grant and does not provide new financial performance data or strategic shifts.

Positives

• Director acquisition of equity signals confidence in the company's future prospects.
• The grant of RSUs is a form of long-term incentive compensation for the director.

Future Outlook

The vesting schedule for the restricted stock units indicates a forward-looking incentive tied to continued service and company performance through at least the first anniversary of the grant date or the 2027 annual meeting.

Industry Context

StockSavvy.ai notes that director equity grants are common within the medical technology sector as a means to align executive and board interests with those of shareholders, particularly for growth-oriented companies like ClearPoint Neuro.

Stakeholder Impact

• Shareholders: The grant of RSUs to a director can be viewed positively as it aligns management incentives with long-term shareholder value creation.

Next Steps

• Vesting of 12,820 restricted stock units on the earlier of the first anniversary of the grant date or the day before the Company's 2027 annual meeting of stockholders.

Key Dates

Keywords

ClearPoint Neuro, CLPT, Form 4, SEC Filing, Restricted Stock Units, RSUs, Director Compensation, Beneficial Ownership, Equity Grant